Tag: febuxostat

 1. Febuxostat was non-inferior to allopurinol for primary cardiovascular endpoints including hospitalization for non-fatal myocardial infarction or biomarker-positive acute coronary syndrome, non-fatal stroke, or cardiovascular death during the treatment period. 2. Treatment with febuxostat was not associated with an increase in cardiovascular or all-cause mortality compared to allopurinol. Evidence Rating Level:...
1. While there was no placebo control group, treatment with febuxostat for 24 months did not slow carotid atherosclerosis progression in Japanese individuals with asymptomatic hyperuricemia.  Evidence Rating Level: 2 (Good) Allopurinol, a purine analogue xanthine oxidase (XO) inhibitor, is a conventional pharmacological intervention for reducing serum uric acid (SUA)...
Viral Load Dynamics and Disease Severity In Patients Infected With SARS-CoV-2 In Zhejiang Province, China, January-March 2020: Retrospective Cohort Study 1. Stool samples demonstrated significantly longer duration of positive viral load than both respiratory and serum samples. 2. Length of positive RNA detection was associated with disease duration with a peak...